Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019 Aug 08, 2019 Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma Aug 01, 2019 Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets Jul 30, 2019 First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology Jun 13, 2019 Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019) Jun 11, 2019 Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting Jun 01, 2019 Nektar Announces the Launch of Inheris Biopharma, Inc. May 23, 2019 Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting May 15, 2019 Nektar Therapeutics Reports Financial Results for the First Quarter of 2019 May 08, 2019 Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets May 01, 2019 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »